[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Gout is a crystal deposition disease. European and Japanese guidelines of management for gout recommend that serum urate concentration should be maintained below 6.0 mg/dL to promote crystal dissolution leading to prevention of recurrent gouty attack. Although allopurinol is recommended to be an adequate drug for urate lowering therapy in all gouty patients by European guideline, it is desirable that allopurinol is indicated in patients with overproduction type and benzbromarone in patients with underexcretion type, recommended by Japanese guideline. Asymptomatic hyperuricemia dose not equate to gout. As there is no evidence to support treatment of isolated hyperuricemia with urate lowering therapy currently, it is difficult to establish lowering goal of serum urate level in patients with asymptomatic hyperuricemia. Advice regarding lifestyle and treatment of associated comorbidity should be preferred to urate lowering therapy. However, urate lowering therapy may be indicated in high risk patients with hyperuricemia who are suffered from hypertension, diabetes mellitus, ischemic heart disease and renal insufficiency.
Fujimori
Shin
S
Department of Internal Medicine, Teikyo University School of Medicine.
D000493:Allopurinol / Q000627:therapeutic use; D001553:Benzbromarone / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D006073:Gout / Q000517:prevention & control / Q000628:therapy*; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000517:prevention & control / Q000628:therapy*; D008019:Life Style; D010347:Patient Care Planning; D017410:Practice Guidelines as Topic; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control; D014527:Uric Acid / Q000097:blood
D006074:Gout Suppressants; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol